Neostigmine

Essential medicine status

Section: 20. Muscle relaxants (peripherally-acting) and cholinesterase inhibitors

EMLc | ATC codes: N07AA01

Indication	Myasthenia gravis ICD11 code: 8C60.Z
INN	Neostigmine bromide
Medicine type	Chemical agent
List type	Core
Formulations	**Parenteral > General injections > unspecified:** 0.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate) ; 2.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate) **Oral > Solid > tablet:** 15 mg (neostigmine bromide) (EML)
EML status history	First added in 1977 (TRS 615) Changed in 1979 (TRS 641) Changed in 1989 (TRS 796) Changed in 2003 (TRS 920) Changed in 2007 (TRS 950) Changed in 2025 (TRS 1064)
Sex	All
Age	Also recommended for children
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more about patents.
Wikipedia	Neostigmine
DrugBank	Neostigmine

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the deletion of neostigmine 15 mg tablets from the EMLc